Does stable metabolic disease on FDG-PET provide information on response to endocrine therapy for breast cancer?
Our data suggest that breast cancer patients under hormonal therapy with stable disease on FDG PET have a longer PFS when compared to non---responders. This finding is new, supporting the value of endocrine therapy among patients with advanced breast cancer.
Metaphase-CGH results confirmed numerous chromosomal aberrations in juvenile angiofibromas. The most frequent aberrations affected sex chromosomes. Further consensus regions of chromosomal aberrations were detected at 4q, 6, 8, 12, 16, 17, and 22. AURKA and MDM2 were identified as interesting novel amplified genes in juvenile angiofibromas.